Nilotinib-d6

• CAT Number: S000116
• CAS Number: 1268356-17-7
• Molecular Formula: C28H16D6F3N7O
• Molecular Weight: 535.55
• Purity: ≥95%
• Target: Autophagy
• IUPAC Name: 2,3,6-trideuterio-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-4-(trideuteriomethyl)benzamide
• InChI: InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)/i1D3,5D,6D,10D
• InChIKey: HHZIURLSWUIHRB-AGINCAKFSA-N
• SMILES: [2H]C1=C(C(=C(C(=C1C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)[2H])NC4=NC=CC(=N4)C5=CN=CC=C5)C([2H])([2H])[2H])[2H]

Nilotinib-d6 (CAS: 1268356-17-7), a premium pharmaceutical research compound designed for advanced oncology studies. As a deuterated analog of Nilotinib, it offers enhanced stability and improved pharmacokinetic properties. Nilotinib-d6 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for chronic myeloid leukemia (CML) and other cancers. Trusted by leading laboratories, Nilotinib-d6 is your go-to solution for cutting-edge cancer research. Unlock new possibilities in leukemia treatment with Nilotinib-d6, where innovation meets reliability.

Reference

[1]. Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20.
[Content Brief]